糖蛋白IIb/IIIa抑制剂在颅内动脉瘤血管内栓塞术中血栓栓塞并发症预防与挽救治疗中的应用
本综述评估了阿昔单抗、依替巴肽和替罗非班在颅内动脉瘤血管内栓塞术中预防和挽救治疗血栓栓塞并发症的文献,认为该类药物预防血栓栓塞有效且安全,但尚无标准化给药方案,并基于既往报告的疗效和颅内出血率给出了给药建议。
要点
- 糖蛋白IIb/IIIa抑制剂用于颅内动脉瘤栓塞术中急性血栓栓塞的挽救治疗及支架、血流导向装置等置入时的缺血预防。
- 已发表的病例报告、病例系列和回顾性综述支持该类药物预防血栓栓塞并发症的有效性和安全性。
- 血管内神经外科尚无标准化的糖蛋白IIb/IIIa抑制剂给药方案。
核心结论
- 已发表文献明确支持糖蛋白IIb/IIIa抑制剂预防血栓栓塞并发症的有效性和安全性,但血管内神经外科尚无标准化给药方案。
研究设计与样本
- 综述,综合评估已发表的关于阿昔单抗、依替巴肽和替罗非班用于血栓栓塞并发症的文献,包括病例报告、病例系列和回顾性综述。
主要发现
- 尽管使用治疗性肝素化和有指征时口服抗血小板治疗,血栓栓塞并发症仍是颅内动脉瘤血管内治疗的主要风险。
- 糖蛋白IIb/IIIa抑制剂靶向血小板黏附和活化后非冗余的聚集通路。
- 该类药物在颅内支架、血流导向装置和致血栓弹簧圈置入时,以及蛛网膜下腔出血和择期动脉瘤栓塞中,作为预防性药物提供缺血保护。
关键数值与推荐
- 基于既往发表的疗效和颅内出血率,提供阿昔单抗、依替巴肽和替罗非班的给药剂量与给药建议。
临床怎么用
- 作者基于既往报告的疗效和颅内出血率,为阿昔单抗、依替巴肽和替罗非班的给药剂量与给药提供了建议。
局限性
- 血管内神经外科尚无标准化的糖蛋白IIb/IIIa抑制剂给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromboembolic complications remain a major risk of endovascular neurosurgery during the treatment of intracranial aneurysms, despite the use of therapeutic heparinization and oral antiplatelet therapy when indicated. Glycoprotein (GP) IIb/IIIa inhibitors target a nonredundant pathway of platelet aggregation following adhesion and activation. Initially established and implemented in the cardiovascular arena, this drug class has provided a new tool in the neurovascular armamentarium as well. Numerous case reports, case series, and retrospective reviews have evaluated the safety and efficacy of abciximab, eptifibatide, and tirofiban in the treatment of acute thromboembolic complications during the endovascular treatment of intracranial aneurysms. The use of this drug class has also been found to be beneficial as a prophylactic agent, providing ischemia protection during the placement of intracranial stents, flow diverters, and thrombogenic coils in the setting of subarachnoid hemorrhage and during elective aneurysmal embolization. While the current published literature clearly establishes efficacy and safety of GP IIb/IIIa inhibitors in the prevention of thromboembolic complications, there does not yet exist an established protocol for their administration in endovascular neurosurgery. This review provides a comprehensive evaluation of the current published literature pertaining to the use of all available GP IIb/IIIa inhibitors for thromboembolic complications, providing recommendations for dosing and administration of abciximab, eptifibatide, and tirofiban based on previously published rates of efficacy and intracranial hemorrhage.
引用
- Dornbos D, Katz JS, Youssef P, et al. Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms. Neurosurgery. 2018. PMID: 28472526. doi:10.1093/neuros/nyx170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。